<DOC>
	<DOCNO>NCT00303667</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine phosphate cyclophosphamide , total body irradiation , peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell natural killer ( NK ) cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Giving IL-2 ( aldesleukin ) NK cell infusion may stimulate kill remain cancer cell . PURPOSE : This phase I/II ( currently enrol phase II ) trial study well donor natural killer cell infusion work treat patient undergo donor stem cell transplant acute myeloid leukemia .</brief_summary>
	<brief_title>Donor Natural Killer Cells Aldesleukin Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine disease-free survival 6 month 1 year patient high-risk myeloid malignancy undergo reduced-intensity haploidentical hematopoietic stem cell transplantation ( HSCT ) supplement donor natural killer ( NK ) cell . Secondary - To evaluate vivo expansion donor CD3- CD19- select NK cell product administer preparative regimen cyclophosphamide , fludarabine , total body irradiation ( TBI ) HSCT patient . - To determine rate graft failure define absolute neutrophil count ( ANC ) &lt; 500/mm³ day 28 . - To determine incidence grade III-IV acute graft-versus-host disease ( GVHD ) 6 month . - To determine rate treatment-related mortality day 100 . - To determine incidence chronic GVHD 12 month . - To determine incidence disease relapse 12 month . - To determine incidence post-transplant lymphoproliferative disorder 12 month . Correlative - To correlate immune reconstitution vivo expand haploidentical NK cell clinical outcome . OUTLINE : This open-label study . Patients receive fludarabine intravenous ( IV ) 1 hour day -18 -14 cyclophosphamide IV 2 hour day -16 -15 . Patients receive cyclosporin A Day -15 Day -8 . Patients undergo total body irradiation day -13 . Patients receive infusion donor natural killer cell day -12 interleukin-2 subcutaneously alternate day day -12 -2 . Patients receive thymoglobulin ( ATG ) undergo allogeneic peripheral blood stem cell transplantation day 0 . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 90 patient accrue study .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>4.2 High risk acute myeloid leukemia ( AML ) fit within one follow disease group : Primary induction failure define complete remission ( CR ) two induction cycle . For primary induction failure ( PIF ) refractory AML , patient must &lt; 5 % circulating blast ( &lt; 1000 absolute circulate blast ) beyond Day 28 last chemo . During workup period circulate blast rise level , patient ineligible . The use hydrea noninduction cytotoxic agent allow reduce blast achieve eligibility . If blast high limit , patient treat alternative therapeutic protocol receive another reinduction attempt . ( See section 7 regard final check blast status within 7 day preparative regimen start ) . Relapsed AML low disease burden must less 5 % marrow blast time enrollment patient receive reinduction measure least 28 day start reinduction therapy patient receive reinduction ( maximum 2 reinduction attempt ) . Patients relapse 12 month follow prior HCT reach CR follow one reinduction cycle le 10 % marrow blast eligible . CR3 great . This include CRp define CR without platelet recovery 100,000/mcL . CR1 CR2 high risk feature ( therapy induce , prior myelodysplastic syndrome [ MDS ] myeloproliferative disease [ MPD ] , high risk cytogenetic molecular phenotype ) available alternate ( sibling , unrelated donor [ URD ] umbilical cord blood [ UCB ] ) donor . Patients prior central nervous system ( CNS ) involvement eligible provide treated CFS must clear least 2 week prior enrollment . Available related HLAhaploidentical donor ( 35 6 HLA , A , B DRB1 match ) Karnofsky performance status &gt; 50 Pulmonary Function : oxygen saturation ≥ room air diffusion lung capacity carbon monoxide ( DLCOcor ) ≥ 40 % Cardiac Function : Ejection fraction ( EF ) ≥ 30 % , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Able prednisone immunosuppressive medication least 3 day prior Day 0 Women child bear potential must negative pregnancy test within 14 day prior study registration agree use adequate birth control study treatment Human antimouse antibody ( HAMA ) monitoring : All subject question prior exposure antibody therapy ( include OKT3 , rituximab , trastuzumab , etc ) . For subject prior antibody therapy exposure , action take For subject receive previous antibody therapy 10 ml serum drawn start therapy . The presence HAMA preclude proceed treatment . Voluntary write consent sign performance study relate procedure part normal medical care . Biphenotypic leukemia New progressive pulmonary infiltrates screen chest xray chest compute tomography ( CT ) scan evaluate bronchoscopy , feasible . Infiltrates attribute infection must stable/improving ( associated clinical improvement ) 1 week appropriate therapy ( 2 week presume documented fungal infection ) . Surgical resection waif wait requirement . Uncontrolled bacterial viral infection . Chronic asymptomatic viral hepatitis allow . Known hypersensitivity study agent use Received investigational drug within 14 day enrollment Donor Selection : 1275 year age &gt; 40 kilogram body weight In general good health determine evaluate physician Donors must HLAA , B , DRB1 haploidentical ( 35/6 antigen HLA , A , B , DRB1 ) match recipient . Patients donor type HLAA , B C use least intermediate resolution DNA techniques DRB1 high ( allele ) resolution . KIR B genotyping do haploidentical donor , feasible , donor favorable KIR gene profile use . Able willing 4 separate apheresis collection per form Not pregnant Human immunodeficiency virus ( HIV ) : HIV1 , HIV2 negative ; HTLV1 , HTLV2 negative , Hepatitis B C negative Voluntary write consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>NK cell</keyword>
	<keyword>natural killer cell</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>hematopoietic cell transplant</keyword>
	<keyword>acute myelogenous leukemia</keyword>
</DOC>